Dr. Al-Ghamrawy:
- We are working to establish a national pharmaceutical industry capable of competing globally.
- Over EGP 500 million invested to bolster the biological products industry in Egypt.
- Modern production lines enhance manufacturing efficiency, with an annual capacity of up to 20 million packs, supporting vital products in the local market.
________________________________________
Dr. Ali Al-Ghamrawy, Chairman of the EDA, conducted a field visit to inaugurate the new production line specialized in eye drops at Pharco Pharmaceuticals Factory in Al-Amriya, Alexandria. The visit reflects the EDA’s commitment to supporting efforts to localize pharmaceutical manufacturing, strengthen partnerships with the national industrial sector, and review the latest manufacturing technologies in line with international standards, thereby enhancing the efficiency of the healthcare system and supporting Egypt’s pharmaceutical security.
The event was attended by Dr. Sherine Helmy, Chairman of Pharco Pharmaceuticals Group, and Dr. Hisham Badr, Vice Chairman of the UPA, along with several EDA leaders, as part of efforts to promote cooperation and integration between state institutions and the industrial sector to support and develop Egypt’s pharmaceutical system.
The visit began with an extensive inspection tour inside Al-Amriya Pharmaceuticals Factory, where the Chairman and the accompanying delegation reviewed the latest production lines and advanced manufacturing technologies. They reviewed operational mechanisms managed in strict accordance with International Quality Standards and Good Manufacturing Practices.

During the tour, Dr. Ali Al-Ghamrawy praised the factory’s technological progress and its adherence to quality standards, emphasizing that the EDA prioritizes supporting national industry through an integrated regulatory system that ensures the quality, efficacy, and safety of pharmaceutical products, placing patient interest at the forefront.
Following the tour, the Chairman participated in the inauguration of the new production line which represents a qualitative addition to Egypt’s pharmaceutical infrastructure.
Key highlights of the project include:
• Production Capacity: Reaching approximately 20 million units annually, significantly meeting local market demands.
• Investment Value: Total investment exceeds EGP 500 million, with approximately EGP 300 million dedicated specifically to this production line.
• Technical Excellence: Designed with precision filling and sealing control systems, ensuring the highest level of product integrity.
Dr. Al-Ghamrawy stated that the rapid progress witnessed by Egypt’s pharmaceutical sector reflects the state’s strategic direction toward building a national pharmaceutical industry capable of competing regionally and internationally. He noted that the EDA continues to fulfill its dual role of regulation and development by encouraging investment in modern production lines.
He added that this project marks a major step toward enhancing the capabilities of the biologics manufacturing sector and supports the state’s direction toward maximizing the role of the private sector as a key partner in achieving sustainable development and building a strong pharmaceutical economy.
The visit concluded with a technical presentation of the production stages, reflecting the EDA’s drive to increase production capacity and open new horizons for exporting Egyptian-made pharmaceuticals to international markets.